Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma

Craig S. Sauter, Matthew J. Matasar, Jessica Meikle, Heiko Schoder, Gary A. Ulaner, Jocelyn C. Migliacci, Patrick Hilden, Sean M. Devlin, Andrew D. Zelenetz, Craig Moskowitz

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.

Original languageEnglish (US)
Pages (from-to)2579-2581
Number of pages3
JournalBlood
Volume125
Issue number16
DOIs
StatePublished - Apr 16 2015
Externally publishedYes

Fingerprint

Chemotherapy
Lymphoma, Large B-Cell, Diffuse
Stem Cell Transplantation
Stem cells
Refractory materials
Cells
Drug Therapy
Disease-Free Survival
Salvaging
Investigational Therapies
Positron emission tomography
Fluorodeoxyglucose F18
Deoxyglucose
Standard of Care
Positron-Emission Tomography
Survival Rate
Imaging techniques
Survival

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. / Sauter, Craig S.; Matasar, Matthew J.; Meikle, Jessica; Schoder, Heiko; Ulaner, Gary A.; Migliacci, Jocelyn C.; Hilden, Patrick; Devlin, Sean M.; Zelenetz, Andrew D.; Moskowitz, Craig.

In: Blood, Vol. 125, No. 16, 16.04.2015, p. 2579-2581.

Research output: Contribution to journalArticle

Sauter, CS, Matasar, MJ, Meikle, J, Schoder, H, Ulaner, GA, Migliacci, JC, Hilden, P, Devlin, SM, Zelenetz, AD & Moskowitz, C 2015, 'Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma', Blood, vol. 125, no. 16, pp. 2579-2581. https://doi.org/10.1182/blood-2014-10-606939
Sauter, Craig S. ; Matasar, Matthew J. ; Meikle, Jessica ; Schoder, Heiko ; Ulaner, Gary A. ; Migliacci, Jocelyn C. ; Hilden, Patrick ; Devlin, Sean M. ; Zelenetz, Andrew D. ; Moskowitz, Craig. / Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. In: Blood. 2015 ; Vol. 125, No. 16. pp. 2579-2581.
@article{ef5fbac988b846e2a62614a02241550c,
title = "Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma",
abstract = "High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77{\%} and 86{\%}, respectively, compared with patients achieving Deauville 4 (49{\%} and 54{\%}, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.",
author = "Sauter, {Craig S.} and Matasar, {Matthew J.} and Jessica Meikle and Heiko Schoder and Ulaner, {Gary A.} and Migliacci, {Jocelyn C.} and Patrick Hilden and Devlin, {Sean M.} and Zelenetz, {Andrew D.} and Craig Moskowitz",
year = "2015",
month = "4",
day = "16",
doi = "10.1182/blood-2014-10-606939",
language = "English (US)",
volume = "125",
pages = "2579--2581",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma

AU - Sauter, Craig S.

AU - Matasar, Matthew J.

AU - Meikle, Jessica

AU - Schoder, Heiko

AU - Ulaner, Gary A.

AU - Migliacci, Jocelyn C.

AU - Hilden, Patrick

AU - Devlin, Sean M.

AU - Zelenetz, Andrew D.

AU - Moskowitz, Craig

PY - 2015/4/16

Y1 - 2015/4/16

N2 - High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.

AB - High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.

UR - http://www.scopus.com/inward/record.url?scp=84927751342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927751342&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-10-606939

DO - 10.1182/blood-2014-10-606939

M3 - Article

C2 - 25758829

AN - SCOPUS:84927751342

VL - 125

SP - 2579

EP - 2581

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -